Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shihuida Pharmaceutical Group (Jilin) Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each pending matter is being handled by a unique examiner within a unique art unit, preventing any single point of contact from dominating the company's patent office interactions. This structure allows for a broader range of examiner feedback across the pending applications.
SHUPE, ELIZABETH A is the busiest examiner for the portfolio. This examiner is responsible for 1 pending office action, which is a portion of the 2 total pending actions currently active for the company. The prosecution workload is evenly split, as no single examiner is managing more than 1 pending action at this time. With 2 distinct art units involved, the company's pending applications are subject to the examination standards of multiple specialized divisions, which may require distinct prosecution approaches for each case within the assigned units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17442461 | PROTEINACEOUS HETERODIMER AND USE THEREOF | GEORGE, DENNIS CHERIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919043 | PREPARATION SPECIFICALLY BOUND WITH CD137 AND USE THEREOF | SHUPE, ELIZABETH A | — |
| 17442461 | PROTEINACEOUS HETERODIMER AND USE THEREOF | GEORGE, DENNIS CHERIAN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17919043 | PREPARATION SPECIFICALLY BOUND WITH CD137 AND USE THEREOF | SHUPE, ELIZABETH A | 1643 | §103Other | Final Rejection | — | Pending | Oct 14, 2022 |
| 17442461 | PROTEINACEOUS HETERODIMER AND USE THEREOF | GEORGE, DENNIS CHERIAN | 1644 | §103§112Other | Final Rejection | — | Pending | Sep 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShihuida Pharmaceutical Group (Jilin) Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Elizabeth A Shupe has the most, with 1 of Shihuida Pharmaceutical Group (Jilin) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
